16 results about "Abzyme" patented technology

The present application relates to the technical field of biotechnology, and particularly relates to a D-dimer chemiluminescence assay kit. The present application provides a D-dimer chemiluminescence assay kit, which comprises a magnetic particle suspension (immunomagnetic beads) coated with D-dimer antibody 1, alkaline phosphatase-labeled D-dimer antibody 2 (enzyme-labeled antibody) and a calibrant. The immunomagnetic beads and the enzyme-labeled antibody are prepared by chemical coupling and stored in a buffer containing a soluble high molecular material, which can effectively improve the detection sensitivity and repeatability. The kit can be used in combination with a substrate solution containing a chromogenic substrate such as adamantane and its derivative AMPPD or APS-5 for a full-automatic immune test system, and the content of D-dimer in plasma or whole blood can be determined by a chemiluminescence instrument. The kit has high detection sensitivity and good repeatability.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

The invention discloses a monoclonal antibody combination for Brucella detection and application thereof, and belongs to the technical field of immunodetection. The monoclonal antibody combination disclosed by the invention comprises a monoclonal antibody 15F4 and a monoclonal antibody 32H9. On the basis of the monoclonal antibody combination, a double-antibody sandwich ELISA detection method with 15F4 as a capture antibody and enzyme-labeled 32H9 as a detection antibody is established, and key parameters such as coating concentration, closing conditions, incubation and color development time and the like are optimized. The method has high specificity on brucella, and does not cross with common cross-reactive bacteria such as escherichia coli O: 157, salmonella and the like; the sensitivity is high, and the detection limit can reach 1 * 10 < 5 > CFU / mL; the repeatability is good, and the intra-batch and inter-batch variation coefficients are both smaller than 10%. The invention provides a core reagent and a reliable means for early, rapid and accurate diagnosis of brucellosis, and is suitable for on-site screening of clinical samples and animal epidemic diseases.

The invention relates to the technical field of biomedical detection, in particular to a preparation method and application of a biotinylated antibody without purification. The specific quenching agent is added into a reaction system, residual active ester is sealed in situ, so that the detection antibody which can be directly used for ELISA is directly obtained, traditional ultrafiltration or gel filtration purification is omitted, the preparation period is shortened by at least 2-3 hours, and activity loss of the antibody caused by centrifugation or dilution is avoided; the residual NHS-ester is quenched in situ by a quenching agent, so that a background signal is remarkably reduced, and the signal-to-noise ratio is improved (the signal-to-noise ratio in an I-C system is improved by more than or equal to 50%); the method provided by the invention can also be popularized to an antibody-enzyme coupling system of heterobifunctional cross-linking agents such as EMCS, Sulfo-SMCC and the like, and the ELISA performance is equivalent to that of a traditional purified product; the kit is suitable for clinical scenes such as acute myocardial infarction needing rapid diagnosis, and a high-throughput and low-cost detection platform can be conveniently established.

This invention belongs to the field of reagent detection technology and discloses a diagnostic kit for P200 type pemphigus. The kit comprises human dermal extract protein strips, LM521 / LM421 / LM411 / LM111 recombinant protein strips, a positive control, a negative control, enzyme-labeled IgG antibody, enzyme-labeled IgA antibody, reaction buffer, washing buffer, and enzyme matrix solution. This invention simplifies the complex immunoblotting technique, using human dermal extract and various LMγ1 recombinant protein mixtures as antigens, and simultaneously analyzing IgG and IgA autoantibodies. It comprehensively solves the serological diagnostic problem of P200 type pemphigus in one step.

The application discloses an antibody protective agent for pre-coated antibody enzyme labeled plates, and the protective agent comprises the following components: 1-4% tetrahydropyrimidine and 4-8% mannitol in terms of mass percentage. The antibody protective agent can effectively improve the storage period and stability of the pre-coated enzyme labeled plate after being opened based on the specific combination of tetrahydropyrimidine and mannitol, and can promote the pre-coated enzyme labeled plate using the antibody protective agent to be stably stored for one month at 25 DEG C after being opened, and the real-time stability at 2-8 DEG C can be as long as 12 months.

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

A compound having the structure (I) is provided. The compound is useful as a therapeutic agent in the form of a lipoplex, or in a form of a polyplex, in a form of a lipid nanoparticle, or in a form of a liposome, or in a form of a micelle, or in a form of an emulsion including a drug, vaccine, oligonucleotide, antibody, enzyme, protein, small molecule, or nucleotide.

This invention relates to a double-antibody sandwich ELISA kit for detecting serum PTGS1 protein, comprising: a PTGS1 capture antibody, an unlabeled PTGS1 detection antibody, an enzyme-labeled IgG secondary antibody, a solid-phase carrier, an enzyme substrate, a blocking buffer, a washing buffer, and a stop solution; the IgG secondary antibody specifically binds to the PTGS1 detection antibody; the PTGS1 capture antibody is a rabbit monoclonal antibody that specifically binds to the linear epitope A of human PTGS1 protein, the amino acid sequence of which is SEQ ID NO:1, corresponding to amino acids 271-282 of human PTGS1 protein; the PTGS1 detection antibody is a mouse monoclonal antibody that specifically binds to the B epitope of human PTGS1 protein; the amino acid sequences of the B epitope at the A epitope do not overlap and do not constitute steric hindrance. This kit avoids the conserved homologous region between PTGS1 and its homologous protein PTGS2, ensuring the accuracy of the capture antibody recognition, and uses an indirect detection mode with enzyme-labeled goat anti-mouse IgG secondary antibody to achieve signal cascade amplification, significantly improving detection sensitivity.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

The invention relates to a double-antibody sandwich ELISA kit for detecting serum PTGS1 protein. The double-antibody sandwich ELISA kit comprises a PTGS1 capture antibody, a non-labeled PTGS1 detection antibody, an enzyme-labeled IgG secondary antibody, a solid-phase carrier, an enzyme substrate, a confining liquid, a washing liquid and a stop solution, the IgG secondary antibody can be specifically combined with the PTGS1 detection antibody; the PTGS1 capture antibody is a rabbit monoclonal antibody specifically combined with a human PTGS1 protein A linear epitope, the amino acid sequence of the A linear epitope is SEQ ID NO: 1, and the A linear epitope corresponds to the 271th to 282th amino acids of the human PTGS1 protein; the PTGS1 detection antibody is a mouse monoclonal antibody which is specifically combined with a human PTGS1 protein B epitope; and the amino acid sequence of the B epitope at the A epitope is not overlapped and does not form steric hindrance. According to the kit, conserved homologous segments of PTGS1 and homologous protein PTGS2 are avoided, the recognition accuracy of a captured antibody is ensured, signal cascade amplification is realized by adopting an indirect detection mode of an enzyme-labeled goat anti-mouse IgG secondary antibody, and the detection sensitivity is remarkably improved.

The application discloses a method for combined analysis of high-sensitivity cardiac troponin and copeptin for non-diagnostic purposes, and belongs to the technical field of protein detection. The method comprises the following steps: separating a plasma sample through centrifugation, preparing a phosphate buffer for dilution, and preparing a sample for detection; constructing an immune analysis system on a multi-well plate by adopting a double-antibody sandwich method, sequentially performing coating, cleaning, blocking, and preparing a standard sample and a labeled antibody; adding the sample and the standard sample into a detection plate, sequentially performing incubation, adding a detection antibody, and adding enzyme-labeled avidin, and finally developing color and measuring absorbance; collecting detection data to establish a standard curve, calculating a sample concentration by using a double-index collaborative correction model, and performing cross-validation and abnormal value processing. According to the scheme, more stable quantitative results can be obtained, and the anti-interference capability of data detection is enhanced.

A method for producing a κ light chain antibody having enzyme activity or improved enzyme activity includes modifying a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is a proline residue, to delete or substitute the proline residue and to obtain a polynucleotide that encodes a κ light chain antibody having a polypeptide having an amino acid sequence where the 95th amino acid residue from the N-terminal of a variable region by the Kabat classification is deleted or substituted with an amino acid residue other than a proline residue, and expressing a κ light chain antibody having enzyme activity in an intracellular or extracellular expression system by using an expression vector including the polynucleotide that encodes a κ light chain antibody obtained after modification.

The application relates to a KIM-1 chemiluminescence kit. The application discloses a KIM-1 chemiluminescence kit, which comprises sample buffer, magnetic bead labeled antibody magnetic bead working solution, alkaline phosphatase coupled kidney injury factor 1 monoclonal antibody enzyme working solution, calibrant and quality control product. The sample buffer comprises reagent 1 and reagent 2. The reagent 1 comprises 2-5% polyethylene glycol-2000, 0.1-0.5% ethylenediaminetetraacetic acid, 5-7% antioxidant IR1010, 50-60% PB buffer, 20-30% toluene and 10-15% formaldehyde. The reagent 2 comprises 5-10% bovine serum albumin, 25-30% NaCl, 3-5% mannitol, 5-10% glycine, 1-5% ethylenediaminetetraacetic acid disodium, 5-9% PVP-10, 30-40% dehydrogenated serum, 0.1-0.5% non-ionic surfactant, 1-5% preservative and 0.1-1.5% LowCross-Buffer. The sample buffer in the KIM-1 chemiluminescence kit prepared by using the application can be used for diluting and storing the sample (urine / serum) after being separated from the body within 0-2h, so that the long-term stability of the sample can be ensured, and the sample is suitable for large-batch detection.